drugset

drugset / Trial / NCT06832410

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

NCT06832410 ↗

Phase 3 Recruiting 10 enrolled Vertex Pharmaceuticals Incorporated

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Timeline

Start: 2025-03-31
Primary completion: 2026-09-17
Completion: 2027-09-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-880	Cell therapy	—	Other

Indications